For research use only. Not for therapeutic Use.
Pivagabine (CXB 722) is a hydrophobic 4-aminobutyric acid derivative with neuromodulatory activity. Pivagabine penetrates the blood-brain barrier in rats. Pivagabine antagonizes the effects of foot shock on both GABAA receptor function and corticotropin-releasing factor (CRF) concentrations in rat brain[1][2].
Pivagabine (CXB 722) (200 mg/kg; i.p.; twice a day for 4 days and 1 hour before killing on the 5th day) prevents the effects of foot-shock stress on CRF concentration in both brain regions[2].
| Catalog Number | I017490 |
| CAS Number | 69542-93-4 |
| Synonyms | 4-(2,2-dimethylpropanoylamino)butanoic acid |
| Molecular Formula | C9H17NO3 |
| Purity | ≥95% |
| InChI | InChI=1S/C9H17NO3/c1-9(2,3)8(13)10-6-4-5-7(11)12/h4-6H2,1-3H3,(H,10,13)(H,11,12) |
| InChIKey | SRPNQDXRVRCTNK-UHFFFAOYSA-N |
| SMILES | CC(C)(C)C(=O)NCCCC(=O)O |
| Reference | [1]. Esposito G, et al. Pivagabine: a novel psychoactive drug. Arzneimittelforschung. 1997 Nov;47(11A):1306-9. [2]. Serra M, et al. Antagonism by pivagabine of stress-induced changes in GABAA receptor function and corticotropin-releasing factor concentrations in rat brain. Psychoneuroendocrinology. 1999 Apr;24(3):269-84. |
